Serum Markers CA153, CA199, CEA, TRAIL, and sFas Along with Inflammatory Cytokines (MIF, Leptin, IL8, HGF, and TNFα) in Lung Cancer

Research Article

Serum Markers CA153, CA199, CEA, TRAIL, and sFas Along with Inflammatory Cytokines (MIF, Leptin, IL8, HGF, and TNFα) in Lung Cancer

  • Freddy Elad Essogmo 1,5*
  • Yvan Sinclair Ngaha Tchawe 1,2
  • Genevieve Kwao-Zigah 3
  • Marina Prokhorova 1
  • Angelina V. Zhilenkova 1
  • Moses Owoicho Abah 1
  • Kingsley Ikenna Uchendu 1
  • Natalia M. Nikitina 1
  • Ineza Laure Isabelle 4
  • Marina I. Sekacheva 1

1Institute for Personalized Oncology, Center for Digital Biodesign and Personalized Healthcare- First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)- 8-2 Trubetskaya str.- Moscow 119991- Russia. 

2Department of Public Health- James Lind Institute- Rue de la Cité 1-1204 Geneva- Switzerland.  

3Department of Biochemistry, Cell and Molecular Biology, University of Ghana.  

4Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Cameroon.  5Cameroon Oncology Center, Douala Cameroon.

*Corresponding Author: Freddy Elad Essogmo, Institute for Personalized Oncology, Center for Digital Biodesign and Personalized Healthcare- First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)- 8-2 Trubetskaya str.- Moscow 119991- Russi

Citation: : Freddy E. Essogmo, Tchawe Y.S.N., Genevieve K. Zigah, Prokhorova M, Angelina V. Zhilenkova, et al. (2025). Serum Markers CA153, CA199, CEA, TRAIL, and sFas Along with Inflammatory Cytokines (MIF, Leptin, IL8, HGF, and TNFα) in Lung Cancer. International Journal of Clinical and Molecular Oncology. BioRes Scientia Publishers. 4(1):1-7. DOI: 10.59657/2993-0197.brs.25.018

Copyright: © 2025 Freddy Elad Essogmo, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: June 26, 2025 | Accepted: July 10, 2025 | Published: July 17, 2025

Abstract

Background: The mortality and morbidity rates of lung cancer are among the highest rates of malignant tumors worldwide. It is very important to put more emphasis on the early diagnosis and treatment of lung cancer. This study aims to provide evidence for the clinical use of conventional serum tumor markers CA15-3, CA199, CEA, TRAIL, and sFas, along with inflammatory cytokines (MIF, Leptin, IL8, HGF, and TNFα) in lung cancer management. 

Methods: From December 2024 to March 2025, 91 lung cancer patients and 100 healthy subjects from Sechenov University’s Institute of Personalized Oncology in Moscow, Russia, were enrolled in this study. Fasting blood samples were collected with the help of a standard venipuncture method to determine its expression in serum. Statistical methods such as the chi-square test, univariate and multivariate analysis, as well as ROC, were used to analyze the data obtained using SPSS version 27. 

Results:  By analysis, the comparison of serum tumor markers CA15-3, CA19-9, CEA, and TRAIL levels were significantly higher in the malignant group than in the healthy group (p< 0.05). Inflammatory markers among the groups showed significantly higher levels of MIF, IL-8, and TNF-α in the cancer cases compared to the healthy control group. 

Conclusion: Serum tumor markers, including CA15-3, CEA, TRAIL, and inflammatory markers, including MIF, IL-8, and TNF-α, were strongly associated with lung cancerAlso, CA15-3, TRAIL, and CEA could be used as a reference indicator for lung cancer diagnosis.


Keywords: lung cancer; CA15-3; MIF; CEA; TNF-α; TRAIL

References